Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.39 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 9/20 | 0.36 |
| ▸ | BCR | P11274 | 9/20 | 0.36 |
| ▸ | TEC | P42680 | 4/20 | 0.35 |
| ▸ | TXK | P42681 | 4/20 | 0.35 |
| ▸ | BMX | P51813 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217102 | 0.91 | BTK (0.35) | BTKNSD2ABL1BCRTEC | |
| SCHEMBL21662833 | 0.91 | BTK (0.35) | BTKNSD2ABL1BCRTEC | |
| SCHEMBL24089358 | 0.88 | KRAS (0.42) | BTKABL1BCR | |
| SCHEMBL24089463 | 0.85 | BTK (0.40) | BTKNSD2 | |
| SCHEMBL24089590 | 0.79 | NSD2 (0.37) | BTKNSD2TECTXKBMX | |
| SCHEMBL31217029 | 0.79 | KRAS (0.40) | BTK | |
| SCHEMBL23909761 | 0.79 | KRAS (0.40) | BTK | |
| SCHEMBL31217076 | 0.77 | USP30 (0.39) | BTK | |
| SCHEMBL23909843 | 0.77 | USP30 (0.39) | BTK | |
| SCHEMBL24089466 | 0.76 | BTK (0.42) | BTKNSD2TECTXKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | KRAS, NRAS, G3BP2 | BTK 2698/4885NSD2 2453/4885ABL1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.